Citations (68)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (4)
Yukinori Endo, Yi Shen, Lamis Abou Youssef, Nishant Mohan & Wen Jin Wu. (2018) T-DM1-resistant cells gain high invasive activity via EGFR and integrin cooperated pathways. mAbs 10:7, pages 1003-1017.
Read now
Read now
Bo Ma, Qianqian Ma, Hongqiang Wang, Guolei Zhang, Huiying Zhang & Xiaohong Wang. (2016) Clinical efficacy and safety of T-DM1 for patients with HER2-positive breast cancer. OncoTargets and Therapy 9, pages 959-976.
Read now
Read now
Elham Mohit, Atieh Hashemi & Mojgan Allahyari. (2014) Breast cancer immunotherapy: monoclonal antibodies and peptide-based vaccines. Expert Review of Clinical Immunology 10:7, pages 927-961.
Read now
Read now
M. J. Rico, H. A. Perroud, L. E. Mainetti, V. R. Rozados & O. G. Scharovsky. (2014) Comparative Effectiveness of Two Metronomic Chemotherapy Schedules—Our Experience in the Preclinical Field. Cancer Investigation 32:3, pages 92-98.
Read now
Read now
Articles from other publishers (64)
Sameen Zafar, Muhammad Armaghan, Khushbukhat Khan, Nazia Hassan, Javad Sharifi-Rad, Solomon Habtemariam, Marek Kieliszek, Monica Butnariu, Iulia-Cristina Bagiu, Radu Vasile Bagiu & William C. Cho. (2023) New insights into the anticancer therapeutic potential of maytansine and its derivatives. Biomedicine & Pharmacotherapy 165, pages 115039.
Crossref
Crossref
Antonio Franco, Alba Di Leone, Marco Conti, Alessandra Fabi, Luisa Carbognin, Andreina Daniela Terribile, Paolo Belli, Armando Orlandi, Martin Alejandro Sanchez, Francesca Moschella, Elena Jane Mason, Giovanni Cimino, Alessandra De Filippis, Fabio Marazzi, Ida Paris, Giuseppe Visconti, Liliana Barone Adesi, Lorenzo Scardina, Sabatino D’Archi, Marzia Salgarello, Diana Giannarelli, Riccardo Masetti & Gianluca Franceschini. (2023) An Innovative Scoring System to Select the Optimal Surgery in Breast Cancer after Neoadjuvant Chemotherapy. Journal of Personalized Medicine 13:8, pages 1280.
Crossref
Crossref
Claudia Parisi, Linda Mahjoubi, Anas Gazzah & Fabrice Barlesi. (2023) TROP-2 directed antibody-drug conjugates (ADCs): The revolution of smart drug delivery in advanced non-small cell lung cancer (NSCLC). Cancer Treatment Reviews 118, pages 102572.
Crossref
Crossref
Chandrasekharan Rajalekshmi Dhanya, Aarcha Shanmugha Mary & Maya Madhavan. (2022)
Aptamer‐siRNA
chimeras: Promising tools for targeting
HER2
signaling in cancer
. Chemical Biology & Drug Design 101:5, pages 1162-1180.
Crossref
Crossref
Wei-Chun Chou & Zhoumeng Lin. (2023) Machine learning and artificial intelligence in physiologically based pharmacokinetic modeling. Toxicological Sciences 191:1, pages 1-14.
Crossref
Crossref
Zeinab Ghesmati, Samira Mokhtari, Maliheh Parvanak, HamidReza Siahkouhi, Mortaza Taheri-Anganeh, Khadijeh Ahmadi, Vahid Zarezade, Farzaneh Vahedi, Zeinab Shajirat, Navid Nezafat & Ahmad Movahedpour. (2022) Designing a humanized immunotoxin based on DELTA-stichotoxin-Hmg2a toxin: an in silico study. Journal of Molecular Modeling 28:12.
Crossref
Crossref
Mingxin Cao, Enyu Shi, Hanping Wang, Lujia Mao, Qiqi Wu, Xinming Li, Yanjie Liang, Xiaoying Yang, Yinsong Wang & Changyi Li. (2022) Personalized Targeted Therapeutic Strategies against Oral Squamous Cell Carcinoma. An Evidence-Based Review of Literature. International Journal of Nanomedicine Volume 17, pages 4293-4306.
Crossref
Crossref
Xiangjun Qi, Yanlong Li, Wei Liu, Yifan Wang, Zhuangzhong Chen & Lizhu Lin. (2022) Research Trend of Publications Concerning Antibody-Drug Conjugate in Solid Cancer: A Bibliometric Study. Frontiers in Pharmacology 13.
Crossref
Crossref
Alessandro Rizzo, Antonio Cusmai, Raffaella Massafra, Samantha Bove, Maria Colomba Comes, Annarita Fanizzi, Gennaro Gadaleta-Caldarola, Donato Oreste, Alfredo Zito, Francesco Giotta, Vito Lorusso & Gennaro Palmiotti. (2022) Systemic Treatments for Metastatic Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Old Certainties and New Frontiers. Cancer Control 29, pages 107327482211062.
Crossref
Crossref
Jindong Xie, Yutian Zou, Ting Gao, Liming Xie, Duxun Tan & Xiaoming Xie. (2022) Therapeutic Landscape of Human Epidermal Growth Factor Receptor 2–Positive Breast Cancer. Cancer Control 29, pages 107327482210992.
Crossref
Crossref
ARUN KUMAR. (2021) COMPREHENSIVE REVIEW ON ETIOPATHOGENESIS, TREATMENT AND EMERGING THERAPIES OF BREAST CANCER. Asian Journal of Pharmaceutical and Clinical Research, pages 20-33.
Crossref
Crossref
James Lu, Kaiwen Deng, Xinyuan Zhang, Gengbo Liu & Yuanfang Guan. (2021) Neural-ODE for pharmacokinetics modeling and its advantage to alternative machine learning models in predicting new dosing regimens. iScience 24:7, pages 102804.
Crossref
Crossref
Yukinori Endo & Wen Jin Wu. (2021) Tumor Extrinsic Factors Mediate Primary T-DM1 Resistance in HER2-Positive Breast Cancer Cells. Cancers 13:10, pages 2331.
Crossref
Crossref
Yukinori Endo, Nishant Mohan, Milos Dokmanovic & Wen Jin Wu. (2021) Mechanisms contributing to ado-trastuzumab emtansine-induced toxicities: a gateway to better understanding of ADC-associated toxicities. Antibody Therapeutics 4:1, pages 55-59.
Crossref
Crossref
Hwa Yeon Jeong, Hyeri Kim, Myunghwa Lee, Jinju Hong, Joo Han Lee, Jeonghyeon Kim, Moon Jung Choi, Yong Serk Park & Sung-Chun Kim. (2020) Development of HER2-Specific Aptamer-Drug Conjugate for Breast Cancer Therapy. International Journal of Molecular Sciences 21:24, pages 9764.
Crossref
Crossref
Shusei Hamamichi, Takeshi Fukuhara & Nobutaka Hattori. (2020) Immunotoxin Screening System: A Rapid and Direct Approach to Obtain Functional Antibodies with Internalization Capacities. Toxins 12:10, pages 658.
Crossref
Crossref
Shuo Cao, Yue-Hui Dong, De-Feng Wang & Zhao-Peng Liu. (2020) Tubulin Maytansine Site Binding Ligands and their Applications as MTAs and ADCs for Cancer Therapy. Current Medicinal Chemistry 27:27, pages 4567-4576.
Crossref
Crossref
Yukinori Endo, Sarah Lyon, Yi Shen, Nishant Mohan & Wen Jin Wu. (2019) Cell proliferation and invasion are regulated differently by EGFR and MRP1 in T-DM1-resistant breast cancer cells. Scientific Reports 9:1.
Crossref
Crossref
Margareth R.C. Marques, Qiuyi Choo, Mukul Ashtikar, Thais Correa Rocha, Susanne Bremer-Hoffmann & Matthias G. Wacker. (2019) Nanomedicines - Tiny particles and big challenges. Advanced Drug Delivery Reviews 151-152, pages 23-43.
Crossref
Crossref
Jiani Wang & Binghe Xu. (2019) Targeted therapeutic options and future perspectives for HER2-positive breast cancer. Signal Transduction and Targeted Therapy 4:1.
Crossref
Crossref
Neelakshi Mungra, Sandra Jordaan, Precious Hlongwane, Krupa Naran, Shivan Chetty & Stefan Barth. (2019) Targeted human cytolytic fusion proteins at the cutting edge: harnessing the apoptosis-inducing properties of human enzymes for the selective elimination of tumor cells. Oncotarget 10:8, pages 897-915.
Crossref
Crossref
Loutfy H. Madkour. 2019. Nucleic Acids as Gene Anticancer Drug Delivery Therapy. Nucleic Acids as Gene Anticancer Drug Delivery Therapy
301
357
.
Francesca Bryden, Camille Martin, Stéphanie Letast, Eva Lles, Inmaculada Viéitez-Villemin, Anaïs Rousseau, Cyril Colas, Marie Brachet-Botineau, Emilie Allard-Vannier, Christel Larbouret, Marie-Claude Viaud-Massuard & Nicolas Joubert. (2018)
Impact of cathepsin B-sensitive triggers and hydrophilic linkers on
in vitro
efficacy of novel site-specific antibody–drug conjugates
. Organic & Biomolecular Chemistry 16:11, pages 1882-1889.
Crossref
Crossref
Xichun Hu, Wei Huang & Minhao Fan. (2017) Emerging therapies for breast cancer. Journal of Hematology & Oncology 10:1.
Crossref
Crossref
Mei S Ong, Wanpei Cai, Yi Yuan, Hin C Leong, Tuan Z Tan, Asad Mohammad, Ming L You, Frank Arfuso, Boon C Goh, Sudha Warrier, Gautam Sethi, Nicholas S Tolwinski, Peter E Lobie, Celestial T Yap, Shing C Hooi, Ruby Y Huang & Alan P Kumar. (2017) ‘Lnc’‐ing Wnt in female reproductive cancers: therapeutic potential of long non‐coding RNAs in Wnt signalling. British Journal of Pharmacology 174:24, pages 4684-4700.
Crossref
Crossref
Nicolas Joubert, Caroline Denevault-Sabourin, Francesca Bryden & Marie-Claude Viaud-Massuard. (2017) Towards antibody-drug conjugates and prodrug strategies with extracellular stimuli-responsive drug delivery in the tumor microenvironment for cancer therapy. European Journal of Medicinal Chemistry 142, pages 393-415.
Crossref
Crossref
Salvatore Vitale, Antonio Laganà, Stella Capriglione, Roberto Angioli, Valentina La Rosa, Salvatore Lopez, Gaetano Valenti, Fabrizio Sapia, Giuseppe Sarpietro, Salvatore Butticè, Carmelo Tuscano, Daniele Fanale, Alessandro Tropea & Diego Rossetti. (2017) Target Therapies for Uterine Carcinosarcomas: Current Evidence and Future Perspectives. International Journal of Molecular Sciences 18:5, pages 1100.
Crossref
Crossref
Hang Zhang, Yuxi Wang, Yangping Wu, Xiaohua Jiang, Yiran Tao, Yuqin Yao, Yujia Peng, Xiangzheng Chen, Yuyin Fu, Lin Yu, Ruixue Wang, Qinhuai Lai, Weirong Lai, Wenting Li, Yuhuan Kang, Shuli Yi, Ying Lu, Lantu Gou, Min Wu & Jinliang Yang. (2017) Therapeutic potential of an anti-HER2 single chain antibody–DM1 conjugates for the treatment of HER2-positive cancer. Signal Transduction and Targeted Therapy 2:1.
Crossref
Crossref
Viviana Masoud & Gilles Pagès. (2017) Targeted therapies in breast cancer: New challenges to fight against resistance. World Journal of Clinical Oncology 8:2, pages 120.
Crossref
Crossref
Alessandra Fabi, Paola Malaguti, Sabrina Vari & Francesco Cognetti. (2016) First-line therapy in HER2 positive metastatic breast cancer: is the mosaic fully completed or are we missing additional pieces?. Journal of Experimental & Clinical Cancer Research 35:1.
Crossref
Crossref
Alison Spellman & Shou-Ching Tang. (2016) Immunotherapy for breast cancer: past, present, and future. Cancer and Metastasis Reviews 35:4, pages 525-546.
Crossref
Crossref
Manal Amoury, Radoslav Mladenov, Thomas Nachreiner, Anh-Tuan Pham, Dmitrij Hristodorov, Stefano Di Fiore, Wijnand Helfrich, Alessa Pardo, Georg Fey, Michael Schwenkert, Theophilus Thepen, Fabian Kiessling, Ahmad F. Hussain, Rainer Fischer, Katharina Kolberg & Stefan Barth. (2016) A novel approach for targeted elimination of CSPG4-positive triple-negative breast cancer cells using a MAP tau-based fusion protein. International Journal of Cancer 139:4, pages 916-927.
Crossref
Crossref
Mei Liu, Zhiyang Li, Jingjing Yang, Yanyun Jiang, Zhongsi Chen, Zeeshan Ali, Nongyue He & Zhifei Wang. (2016) Cell-specific biomarkers and targeted biopharmaceuticals for breast cancer treatment. Cell Proliferation 49:4, pages 409-420.
Crossref
Crossref
V. Sibaud, S. Nougarolis, C. Borjesson, D. Gangloff, J.P. Delord, V. Pompa, D. Saintenac & H. Roche. (2015)
T‐
DM
1 extravasation: first description
. Journal of the European Academy of Dermatology and Venereology 30:7, pages 1235-1236.
Crossref
Crossref
David Y. Jackson. (2016) Processes for Constructing Homogeneous Antibody Drug Conjugates. Organic Process Research & Development 20:5, pages 852-866.
Crossref
Crossref
Haoheng Yan, Yukinori Endo, Yi Shen, David Rotstein, Milos Dokmanovic, Nishant Mohan, Partha Mukhopadhyay, Bin Gao, Pal Pacher & Wen Jin Wu. (2016) Ado-Trastuzumab Emtansine Targets Hepatocytes Via Human Epidermal Growth Factor Receptor 2 to Induce Hepatotoxicity. Molecular Cancer Therapeutics 15:3, pages 480-490.
Crossref
Crossref
Mar?a Teresa Mart?nez, Jos? Alejandro P?rez-Fidalgo, Paloma Mart?n-Martorell, Juan Miguel Cejalvo, Vanesa Pons, Bego?a Bermejo, Miguel Mart?n, Joan Albanell & Ana Lluch. (2016) Treatment of HER2 positive advanced breast cancer with T-DM1: A review of the literature. Critical Reviews in Oncology/Hematology 97, pages 96-106.
Crossref
Crossref
S.P. Egusquiaguirre, J.L. Pedraz, R.M. Hernández & M. Igartua. 2016. Nanoarchitectonics for Smart Delivery and Drug Targeting. Nanoarchitectonics for Smart Delivery and Drug Targeting
813
869
.
Yuqin Yao, Lin Yu, Xiaolan Su, Yuxi Wang, Wenting Li, Yangpin Wu, Xiangzheng Cheng, Hang Zhang, Xian Wei, Hao Chen, Rundong Zhang, Lantu Gou, Xiaoxin Chen, Yongmei Xie, Bo Zhang, Yonghui Zhang, Jinliang Yang & Yuquan Wei. (2015) Synthesis, characterization and targeting chemotherapy for ovarian cancer of trastuzumab-SN-38 conjugates. Journal of Controlled Release 220, pages 5-17.
Crossref
Crossref
Laura Cosmai, Maurizio Gallieni & Camillo Porta. (2015) Renal toxicity of anticancer agents targeting HER2 and EGFR. Journal of Nephrology 28:6, pages 647-657.
Crossref
Crossref
Lei ZhengAndrew Lupo & Lei Zheng. 2015. Monoclonal Antibodies: Development, Delivery and Applications. Monoclonal Antibodies: Development, Delivery and Applications
156
165
.
Matthew Trendowski. (2015) Recent Advances in the Development of Antineoplastic Agents Derived from Natural Products. Drugs 75:17, pages 1993-2016.
Crossref
Crossref
Chien-Hsun WuYi-Huei KuoRuey-Long HongHan-Chung Wu. (2015) α-Enolase–binding peptide enhances drug delivery efficiency and therapeutic efficacy against colorectal cancer. Science Translational Medicine 7:290.
Crossref
Crossref
Camillo Porta, Laura Cosmai, Maurizio Gallieni, Paolo Pedrazzoli & Fabio Malberti. (2015) Renal effects of targeted anticancer therapies. Nature Reviews Nephrology 11:6, pages 354-370.
Crossref
Crossref
Gregory M. Cockrell, Michael S. Wolfe, Janet L. Wolfe & Christian Schöneich. (2015) Photoinduced Aggregation of a Model Antibody–Drug Conjugate. Molecular Pharmaceutics 12:6, pages 1784-1797.
Crossref
Crossref
Edgar Pérez-Herrero & Alberto Fernández-Medarde. (2015) Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy. European Journal of Pharmaceutics and Biopharmaceutics 93, pages 52-79.
Crossref
Crossref
Rinpei Niwa & Mitsuo Satoh. (2015) The Current Status and Prospects of Antibody Engineering for Therapeutic Use: Focus on Glycoengineering Technology. Journal of Pharmaceutical Sciences 104:3, pages 930-941.
Crossref
Crossref
Cristina Santos, Rebeca Sanz-Pamplona, Ernest Nadal, Julieta Grasselli, Sonia Pernas, Rodrigo Dienstmann, Victor Moreno, Josep Tabernero & Ramon Salazar. (2015) Intrinsic cancer subtypes-next steps into personalized medicine. Cellular Oncology 38:1, pages 3-16.
Crossref
Crossref
Roberta Nicoletti, Salvatore Lopez, Stefania Bellone, Emiliano Cocco, Carlton L. Schwab, Jonathan D. Black, Floriana Centritto, Liancheng Zhu, Elena Bonazzoli, Natalia Buza, Pei Hui, Delia Mezzanzanica, Silvana Canevari, Peter E. Schwartz, Thomas J. Rutherford & Alessandro D. Santin. (2014) T-DM1, a novel antibody-drug conjugate, is highly effective against uterine and ovarian carcinosarcomas overexpressing HER2. Clinical & Experimental Metastasis 32:1, pages 29-38.
Crossref
Crossref
Jonathan D. Black, Dana M. Roque, Leslie I. Gold & Alessandro D. Santin. 2018. Uterine Cancer. Uterine Cancer
259
271
.
Thuy Vu, Mark X. Sliwkowski & Francois X. Claret. (2014) Personalized drug combinations to overcome trastuzumab resistance in HER2-positive breast cancer. Biochimica et Biophysica Acta (BBA) - Reviews on Cancer 1846:2, pages 353-365.
Crossref
Crossref
Darshil T. Jhaveri, Lei Zheng & Elizabeth M. Jaffee. (2014) Specificity Delivers: Therapeutic Role of Tumor Antigen-Specific Antibodies in Pancreatic Cancer. Seminars in Oncology 41:5, pages 559-575.
Crossref
Crossref
Simona Moga, Stephanie Juhasz-B?ss, David Bardens, Nicole Kranzh?fer, Sogand Nemat, Erich-Franz Solomayer & Ingolf Juhasz-B?ss. (2014) Trastuzumab (herceptin): a retrospective analysis of the effects of long-term application in a series of patients with breast cancer. Archives of Gynecology and Obstetrics 290:4, pages 733-739.
Crossref
Crossref
Sophie B. Sun, Peter G. Schultz & Chan Hyuk Kim. (2014) Therapeutic Applications of an Expanded Genetic Code. ChemBioChem 15:12, pages 1721-1729.
Crossref
Crossref
Helmout Modjtahedi, Byoung Chul Cho, Martin C. Michel & Flavio Solca. (2014) A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. Naunyn-Schmiedeberg's Archives of Pharmacology 387:6, pages 505-521.
Crossref
Crossref
Dimitrios Tryfonopoulos. (2014) Antibody?cytotoxic drug conjugates in clinical trials and future perspectives: the development of Trojan horses. memo - Magazine of European Medical Oncology 7:1, pages 47-49.
Crossref
Crossref
Gonzalo Recondo Jr. (2014) Therapeutic options for HER-2 positive breast cancer: Perspectives and future directions. World Journal of Clinical Oncology 5:3, pages 440.
Crossref
Crossref
Jonathan D Black, Diana P English, Dana M Roque & Alessandro D Santin. (2014) Targeted Therapy in Uterine Serous Carcinoma: An Aggressive Variant of Endometrial Cancer. Women's Health 10:1, pages 45-57.
Crossref
Crossref
Joanne Bronson, Amelia Black, Murali Dhar, Bruce Ellsworth & J. Robert Merritt. 2014.
437
508
.
Eugenia Ch Yiannakopoulou. 2014. Omics Approaches in Breast Cancer. Omics Approaches in Breast Cancer
483
498
.
Brian Godman, Alexander E Finlayson, Parneet K Cheema, Eva Zebedin-Brandl, Inaki Gutiérrez-Ibarluzea, Jan Jones, Rickard E Malmström, Elina Asola, Christoph Baumgärtel, Marion Bennie, Iain Bishop, Anna Bucsics, Stephen Campbell, Eduardo Diogene, Alessandra Ferrario, Jurij Fürst, Kristina Garuoliene, Miguel Gomes, Katharine Harris, Alan Haycox, Harald Herholz, Krystyna Hviding, Saira Jan, Marija Kalaba, Christina Kvalheim, Ott Laius, Sven-Ake Lööv, Kamila Malinowska, Andrew Martin, Laura McCullagh, Fredrik Nilsson, Ken Paterson, Ulrich Schwabe, Gisbert Selke, Catherine Sermet, Steven Simoens, Dominik Tomek, Vera Vlahovic-Palcevski, Luka Voncina, Magdalena Wladysiuk, Menno van Woerkom, Durhane Wong-Rieger, Corrine Zara, Raghib Ali & Lars L Gustafsson. (2013) Personalizing health care: feasibility and future implications. BMC Medicine 11:1.
Crossref
Crossref
A.L. Risinger, J. Li, M.J. Bennett, C.C. Rohena, J. Peng, D.C. Schriemer & S.L. Mooberry. (2013)
Taccalonolide Binding to Tubulin Imparts Microtubule Stability and Potent
In Vivo
Activity
. Cancer Research 73:22, pages 6780-6792.
Crossref
Crossref
Jianliang Zhang & Steven N. Hochwald. (2013) Targeting Receptor Tyrosine Kinases in Solid Tumors. Surgical Oncology Clinics of North America 22:4, pages 685-703.
Crossref
Crossref
Jia Su, Peiji Zhao, Lingmei Kong, Xingyao Li, Juming Yan, Ying Zeng & Yan Li. (2013) Trichothecin Induces Cell Death in NF-κB Constitutively Activated Human Cancer Cells via Inhibition of IKKβ Phosphorylation. PLoS ONE 8:8, pages e71333.
Crossref
Crossref